Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Nocebo effect and biosimilars in inflammatory bowel diseases: what’s new and what’s next?
Ferdinando D’Amico, Virginia Solitano, Laurent Peyrin‐Biroulet, et al.
Expert Opinion on Biological Therapy (2020) Vol. 21, Iss. 1, pp. 47-55
Closed Access | Times Cited: 18

Showing 18 citing articles:

Biosimilars in IBD: What Every Clinician Needs to Know
Anthony Angyal, Shubha Bhat
Current Gastroenterology Reports (2024) Vol. 26, Iss. 3, pp. 77-85
Closed Access | Times Cited: 8
Risk factors associated with nocebo effects: A review of reviews
Francesca Grosso, Diletta Barbiani, Cesare Cavalera, et al.
Brain Behavior & Immunity - Health (2024) Vol. 38, pp. 100800-100800
Open Access | Times Cited: 7
Comparison of Performances of Adalimumab Biosimilars SB5, ABP501, GP2017, and MSB11022 in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational Study
Antonio Tursi, Giammarco Mocci, Leonardo Allegretta, et al.
Inflammatory Bowel Diseases (2022) Vol. 29, Iss. 3, pp. 376-383
Closed Access | Times Cited: 20
Biobetters and biosimilars in Inflammatory Bowel Disease
Jacopo Fanizza, Ilaria Faggiani, Mariangela Allocca, et al.
Best Practice & Research Clinical Gastroenterology (2025), pp. 101992-101992
Closed Access
Unlocking hope: The future of ustekinumab biosimilars in Crohn's disease treatment
Fabrizio Fanizzi, Sarah Bencardino, André Gonçalves, et al.
United European Gastroenterology Journal (2025)
Open Access
Clinical outcomes and cost savings of a nonmedical switch to a biosimilar in children/young adults with inflammatory bowel disease
Megan McNicol, Mahmoud Abdel‐Rasoul, Madeline G. McClinchie, et al.
Journal of Pediatric Gastroenterology and Nutrition (2024) Vol. 78, Iss. 3, pp. 644-652
Closed Access | Times Cited: 2
Biosimilar switching in inflammatory bowel disease: from evidence to clinical practice
Virginia Solitano, Ferdinando D’Amico, Gionata Fiorino, et al.
Expert Review of Clinical Immunology (2020) Vol. 16, Iss. 10, pp. 1019-1028
Closed Access | Times Cited: 18
Replacement of Adalimumab Originator to Adalimumab Biosimilar for a Non-Medical Reason in Patients with Inflammatory Bowel Disease: A Real-life Comparison of Adalimumab Biosimilars Currently Available in Italy
Antonio Tursi, Giammarco Mocci, Antonio Cuomo, et al.
Journal of Gastrointestinal and Liver Diseases (2022) Vol. 31, Iss. 4, pp. 411-416
Open Access | Times Cited: 12
Moving forward: Implementing health psychology research to improve patient acceptance of biosimilars
Chiara Gasteiger, Keith J. Petrie
Research in Social and Administrative Pharmacy (2022) Vol. 18, Iss. 10, pp. 3860-3863
Closed Access | Times Cited: 11
Adalimumab Biosimilar GP2017 versus Adalimumab Originator in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational Study
Giammarco Mocci, Giorgia Bodini, Leonardo Allegretta, et al.
Biomedicines (2022) Vol. 10, Iss. 8, pp. 1799-1799
Open Access | Times Cited: 11
Nocebo response intensity and influencing factors in the randomized clinical trials of irritable bowel syndrome: A systematic review and meta-analysis
Ruijie Li, Fuping Chen, Xuanxuan He, et al.
Frontiers in Medicine (2022) Vol. 9
Open Access | Times Cited: 9
The 2023 Impact of Inflammatory Bowel Disease in Canada: Treatment Landscape
Sanjay K. Murthy, Adam V. Weizman, M Ellen Kuenzig, et al.
Journal of the Canadian Association of Gastroenterology (2023) Vol. 6, Iss. Supplement_2, pp. S97-S110
Open Access | Times Cited: 5
Practical Management of Biosimilar Use in Inflammatory Bowel Disease (IBD): A Global Survey and an International Delphi Consensus
Ferdinando D’Amico, Virginia Solitano, Fernando Magro, et al.
(2023)
Open Access | Times Cited: 4
Clinical experience of using biosimilars in Crohn’s disease and their effectiveness
Léa Sequier, Bénédicte Caron, Silvio Danese, et al.
Expert Opinion on Biological Therapy (2024), pp. 1-25
Closed Access
Considerations when starting patients on multiple biologics and small molecules
Sudheer K. Vuyyuru, Saurabh Kedia, Vineet Ahuja
Current Opinion in Gastroenterology (2022)
Closed Access | Times Cited: 1
Nocebo effect in health communication: how to minimize it?
Bruna Alves Rodrigues, Luciana Micaelly Costa Pessoa Silva, Hiênio Ítalo da Silva Lucena, et al.
Revista CEFAC (2022) Vol. 24, Iss. 4
Open Access | Times Cited: 1
Applying Placebo and Nocebo Effects From Randomized Trials to Clinical Care and Future Studies
Christopher Ma
The American Journal of Gastroenterology (2022) Vol. 118, Iss. 4, pp. 610-612
Closed Access | Times Cited: 1
Efeito nocebo na comunicação em saúde: como minimizá-lo?
Bruna Alves Rodrigues, Luciana Micaelly Costa Pessoa Silva, Hiênio Ítalo da Silva Lucena, et al.
Revista CEFAC (2022) Vol. 24, Iss. 4
Open Access
Page 1

Scroll to top